Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Receivables (2021 - 2023)

Historic Change in Receivables for Relay Therapeutics (RLAY) over the last 3 years, with Q4 2023 value amounting to -$211000.0.

  • Relay Therapeutics' Change in Receivables fell 42461.54% to -$211000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$306000.0, marking a year-over-year decrease of 21546.39%. This contributed to the annual value of -$306000.0 for FY2023, which is 21546.39% down from last year.
  • Latest data reveals that Relay Therapeutics reported Change in Receivables of -$211000.0 as of Q4 2023, which was down 42461.54% from $133000.0 recorded in Q3 2023.
  • In the past 5 years, Relay Therapeutics' Change in Receivables ranged from a high of $525000.0 in Q3 2021 and a low of -$75.0 million during Q1 2021
  • Its 3-year average for Change in Receivables is -$6.3 million, with a median of -$33500.0 in 2022.
  • Within the past 5 years, the most significant YoY rise in Relay Therapeutics' Change in Receivables was 38297.87% (2023), while the steepest drop was 119473.68% (2023).
  • Quarter analysis of 3 years shows Relay Therapeutics' Change in Receivables stood at -$401000.0 in 2021, then soared by 116.21% to $65000.0 in 2022, then tumbled by 424.62% to -$211000.0 in 2023.
  • Its last three reported values are -$211000.0 in Q4 2023, $133000.0 for Q3 2023, and -$208000.0 during Q2 2023.